“We are delighted that clinical evidence supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections will be presented ...
YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
ABERDEEN, ABERDEEN CITY, SCOTLAND, April 21, 2022 /EINPresswire.com / -- New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in ...
New data shows the Accelerate Arc System enables automated and rapid sample preparation that yields robust reportability and accurate microbial identification for positive blood cultures using MALDI ...
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Geom Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of novel antibiotics for multidrug-resistant (MDR) ...
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate ...
Preanalytics – sample collection, processing, and other activities that make samples analyzable by diagnostics platforms – is one of the first steps of the intricate path to a correct diagnosis. Thus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results